Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study

被引：5

作者：

Okauchi, Shinichiro ^{[1
]}

Numata, Takeshi ^{[2
,3
]}

Nawa, Takeshi ^{[4
,5
]}

Ichimura, Hideo ^{[4
,5
]}

Saito, Takefumi ^{[6
]}

Hayashihara, Kenji ^{[6
]}

Yamada, Hideyasu ^{[7
]}

Satoh, Hiroaki ^{[1
]}

Endo, Takeshi ^{[2
,3
]}

Inage, Yoshihisa ^{[2
,3
]}

Kaburagi, Takayuki ^{[8
]}

Kiyoshima, Moriyuki ^{[8
]}

Yamada, Yutaka ^{[8
]}

Tamura, Tomohiro ^{[8
]}

Saito, Kazuhito ^{[9
,10
]}

Inagaki, Masaharu ^{[9
,10
]}

Hizawa, Nobuyuki ^{[11
]}

Sato, Yukio ^{[11
]}

Shiozawa, Toshihiro ^{[11
]}

Sekine, Ikuo ^{[11
]}

Ishikawa, Hiroichi ^{[12
,13
]}

Kurihima, Koichi ^{[12
,13
]}

Sakai, Mitsuaki ^{[12
,13
]}

Kamiyama, Koichi ^{[14
]}

Kimura, Masaki ^{[14
]}

Kikuchi, Norihiro ^{[15
]}

Nakamura, Hiroyuki ^{[16
,17
]}

Furukawa, Kinya ^{[16
,17
]}

Kodama, Takahide ^{[18
]}

Miyazaki, Kunihiko ^{[18
]}

Yamashita, Takaaki ^{[19
]}

Hayashi, Shigen ^{[20
]}

Funayama, Yasunori ^{[21
]}

Nomura, Akihiro ^{[20
]}

机构：

[1] Univ Tsukuba, Mito Kyodo Gen Hosp, Mito Med Ctr, Div Resp Med, Mito, Ibaraki, Japan

[2] Mito Med Ctr, Div Resp Med, Mito, Ibaraki, Japan

[3] Mito Med Ctr, Div Thorac Surg, Mito, Ibaraki, Japan

[4] Hitachi Gen Hosp, Div Resp Med, Hitachi, Ibaraki, Japan

[5] Hitachi Gen Hosp, Div Thorac Surg, Hitachi, Ibaraki, Japan

[6] Ibarakihigashi Hosp, Div Resp Med, Tokai, Ibaraki, Japan

[7] Univ Tsukuba, Div Resp Med, Hitachinaka Med Ctr, Mito, Ibaraki, Japan

[8] Ibaraki Cent Hosp, Resp Ctr, Kasama, Ibaraki, Japan

[9] Tsuchiura Kyodo Gen Hosp, Div Resp Med, Tsuchiura, Ibaraki, Japan

[10] Tsuchiura Kyodo Gen Hosp, Div Thorac Surg, Tsuchiura, Ibaraki, Japan

[11] Univ Tsukuba, Fac Clin Med, Tsukuba, Ibaraki, Japan

[12] Tsukuba Med Ctr Hosp, Div Resp Med, Tsukuba, Ibaraki, Japan

[13] Tsukuba Med Ctr Hosp, Div Thorac Surg, Tsukuba, Ibaraki, Japan

[14] Tsukuba Kinen Hosp, Div Thorac Surg, Tsukuba, Ibaraki, Japan

[15] Kasumigaura Med Ctr, Div Resp Med, Tsuchiura, Ibaraki, Japan

[16] Tokyo Med Univ, Ibaraki Med Ctr, Div Resp Med, Ami, Ibaraki, Japan

[17] Tokyo Med Univ, Ibaraki Med Ctr, Div Thorac Surg, Ami, Ibaraki, Japan

[18] Ryugasaki Saiseikai Hosp, Div Resp Med, Ryugasaki, Japan

[19] JA Toride Med Ctr, Div Resp Med, Toride, Japan

[20] Seinan Med Ctr, Div Resp Med, Sakai, Osaka, Japan

[21] Tsukuba Gakuen Gen Hosp, Div Resp Med, Tsukuba, Ibaraki, Japan

来源：

ANTICANCER RESEARCH | 2020年 / 40卷 / 02期

关键词：

Clinical practice; alectinib; non-small cell lung cancer; anaplastic lymphoma kinase fusion gene mutation; chemotherapy; KINASE INHIBITION; TYROSINE KINASE; CRIZOTINIB; THERAPY; CHEMOTHERAPY; ALECTINIB; SURVIVAL;

D O I：

10.21873/anticanres.14029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: To describe real clinical outcomes when using systemic therapy to treat non-small cell lung cancer (NSCLC) patients who have anaplastic lymphoma kinase (ALK) fusion gene mutation. Patients and Methods: We performed a retrospective chart review from April 2008 to March 2019 sourced from 16 medical institutes that cover a population of three million people. Results: There were 129 ALK rearranged NSCLC patients. Among them, 103 patients including 40 recurrent disease cases received ALK-tyrosine kinase inhibitors (TKI) and chemotherapy. Our treatment results were comparable to previously reported clinical trials and clinical practice studies. First-line alectinib, treatment sequence of ALK-TKI followed by another ALK-TKI, and pemetrexed-containing chemotherapy contributed to the outcome of treatment. Conclusion: By arrangement of treatment such as treatment sequence of ALK-TKI and chemotherapy regimen, it might be possible to obtain a treatment outcome almost equivalent to those of clinical trials even in real clinical practice.

引用

下载

页码：957 / 964

页数：8

共 50 条

[1] CERITINIB EXHIBITS RESPONSES IN PATIENTS WITH ALK-REARRANGED NSCLC
不详
CANCER DISCOVERY, 2016, 6 (09) : 943 - 943
[2] CERITINIB IS EFFECTIVE IN ALK-REARRANGED NSCLC
不详
CANCER DISCOVERY, 2014, 4 (06) : 632 - 632
[3] Treatment and detection of ALK-rearranged NSCLC
Peters, Solange
Taron, Miguel
Bubendorf, Lukas
Blackhall, Fiona
Stahel, Rolf
LUNG CANCER, 2013, 81 (02) : 145 - 154
[4] Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice
Jamme, Philippe
Descarpentries, Clotilde
Gervais, Radj
Dansin, Eric
Wislez, Marie
Gregoire, Valerie
Richard, Nicolas
Baldacci, Simon
Rabbe, Nathalie
Kyheng, Maeva
Kherrouche, Zoulika
Escande, Fabienne
Copin, Marie Christine
Cortot, Alexis B.
CLINICAL LUNG CANCER, 2019, 20 (04) : 297 - +
[5] Treatment Algorithm for Advanced ALK-Rearranged NSCLC
Urbanska, Edyta Maria
Sorensen, Jens Benn
Santoni-Rugiu, Eric
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (09) : E156 - E157
[6] Treatment Algorithm for Advanced ALK-Rearranged NSCLC: Reply
Zhou, Fei
Zhou, Caicun
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (09) : E157 - E158
[7] A selective ALK inhibitor in ALK-rearranged patients
Yang, James Chih-Hsin
LANCET ONCOLOGY, 2013, 14 (07): : 564 - 565
[8] Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC
Konig, David
Meier, Urs R.
Klaeser, Bernd
Savic, Spasenija
Pless, Miklos
CASE REPORTS IN ONCOLOGY, 2020, 13 (02): : 729 - 732
[9] Adjuvant Alectinib in ALK-Rearranged NSCLC - Here and Now
Passaro, Antonio
Peters, Solange
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (14): : 1325 - 1327
[10] Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients-A Retrospective Observational Study
Siringo, Marco
Gentile, Gabriella
Caponnetto, Salvatore
Sperduti, Isabella
Santini, Daniele
Cortesi, Enrico
Gelibter, Alain Jonathan
CANCERS, 2023, 15 (13)

← 1 2 3 4 5 →